95 related articles for article (PubMed ID: 25110097)
1. Components of the RANK/RANKL/OPG system, IL-6, IL-8, IL-16, MMP-2, and calcitonin in the sera of patients with bone tumors.
Kushlinskii NE; Timofeev YS; Solov'ev YN; Gerstein ES; Lyubimova NV; Bulycheva IV
Bull Exp Biol Med; 2014 Aug; 157(4):520-3. PubMed ID: 25110097
[TBL] [Abstract][Full Text] [Related]
2. Key Immune Checkpoint PD-1/PD-L1 Signaling Pathway Components in the Blood Serum from Patients with Bone Tumors.
Kushlinskii NE; Alferov AA; Timofeev YS; Gershtein ES; Bulycheva IV; Bondarev AV; Shchupak MY; Sokolov NY; Polikarpova SB; Efimova MM; Dzampaev AA; Sushentsov EA; Aliev MD; Musaev ER
Bull Exp Biol Med; 2020 Nov; 170(1):64-68. PubMed ID: 33231796
[TBL] [Abstract][Full Text] [Related]
3. Assessment and clinical implications of RANK/RANKL/OPG pathway as markers of bone tumor progression in patients with NET harboring bone metastases.
Milone F; Pivonello C; Cariati F; Sarnataro M; Ramundo V; Marotta V; Jann H; Pape UF; Wiedenmann B; Colao A; Pavel M; Faggiano A
Biomarkers; 2013 Mar; 18(2):121-5. PubMed ID: 23336103
[TBL] [Abstract][Full Text] [Related]
4. Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis.
Li X; Liu Y; Wu B; Dong Z; Wang Y; Lu J; Shi P; Bai W; Wang Z
Oncol Rep; 2014 Dec; 32(6):2605-11. PubMed ID: 25333856
[TBL] [Abstract][Full Text] [Related]
5. Receptor Activator of Nuclear Transcription Factor NF-κB (RANK), Its Ligand RANKL, and Natural Inhibitor of RANKL Osteoprotegerin (OPG) in the Blood Serum of Patients with Primary Bone Tumors.
Kushlinskii NE; Gershtein ES; Solov'ev YN; Timofeev YS; Babkina IV; Dolinkin AO; Zuev AA; Kostyleva OI
Bull Exp Biol Med; 2017 Aug; 163(4):478-481. PubMed ID: 28853064
[TBL] [Abstract][Full Text] [Related]
6. RANKL/RANK/OPG system and bone status in females with anorexia nervosa.
Ostrowska Z; Ziora K; Oświęcimska J; Swiętochowska E; Szapska B; Wołkowska-Pokrywa K; Dyduch A
Bone; 2012 Jan; 50(1):156-60. PubMed ID: 22001124
[TBL] [Abstract][Full Text] [Related]
7. Serum receptor activator of nuclear factor κB ligand (RANKL) levels predict biochemical recurrence in patients undergoing radical prostatectomy.
Todenhöfer T; Hennenlotter J; Leidenberger P; Wald A; Hohneder A; Kühs U; Mischinger J; Aufderklamm S; Gakis G; Blumenstock G; Stenzl A; Schwentner C
BJU Int; 2014 Jan; 113(1):152-9. PubMed ID: 23360112
[TBL] [Abstract][Full Text] [Related]
8. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
Kim JG; Kim JH; Kim JY; Ku SY; Jee BC; Suh CS; Kim SH; Choi YM
Menopause; 2007; 14(5):913-8. PubMed ID: 17667143
[TBL] [Abstract][Full Text] [Related]
9. Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: a bone damage biomarker?
Spelling P; Bonfá E; Caparbo VF; Pereira RM
Scand J Rheumatol; 2008; 37(6):439-44. PubMed ID: 18802807
[TBL] [Abstract][Full Text] [Related]
10. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
[TBL] [Abstract][Full Text] [Related]
11. Expression of the melatonin receptor (MT) 1 in benign and malignant human bone tumors.
Toma CD; Svoboda M; Arrich F; Ekmekcioglu C; Assadian O; Thalhammer T
J Pineal Res; 2007 Sep; 43(2):206-13. PubMed ID: 17645699
[TBL] [Abstract][Full Text] [Related]
12. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis.
Rutkowski P; Kamińska J; Kowalska M; Ruka W; Steffen J
J Surg Oncol; 2003 Nov; 84(3):151-9. PubMed ID: 14598359
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of the osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, metalloproteinase-1 (MMP-1) and tissue inhibitors of MMP-1 levels are increased in men 6 months after acute myocardial infarction.
Halapas A; Zacharoulis A; Theocharis S; Karavidas A; Korres D; Papadopoulos K; Katopodis H; Stavropoulou A; Lembessis P; Xiromeritis C; Zacharoulis A; Koutsilieris M
Clin Chem Lab Med; 2008; 46(4):510-6. PubMed ID: 18298349
[TBL] [Abstract][Full Text] [Related]
14. Osteoprotegerin/RANK/RANKL axis in cardiac remodeling due to immuno-inflammatory myocardial disease.
Liu W; Feng W; Wang F; Li W; Gao C; Zhou B; Ma M
Exp Mol Pathol; 2008 Jun; 84(3):213-7. PubMed ID: 18417124
[TBL] [Abstract][Full Text] [Related]
15. High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis.
Ishii R; Morimoto A; Ikushima S; Sugimoto T; Asami K; Bessho F; Kudo K; Tsunematu Y; Fujimoto J; Imashuku S
Pediatr Blood Cancer; 2006 Aug; 47(2):194-9. PubMed ID: 16358318
[TBL] [Abstract][Full Text] [Related]
16. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
Mountzios G; Dimopoulos MA; Bamias A; Papadopoulos G; Kastritis E; Syrigos K; Pavlakis G; Terpos E
Acta Oncol; 2007; 46(2):221-9. PubMed ID: 17453373
[TBL] [Abstract][Full Text] [Related]
17. Changes in serum levels of receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, IL-6 and TNF-alpha in patients with a concomitant head injury and fracture.
Lee JS; Ryu CH; Moon NH; Kim SJ; Park SY; Suh KT
Arch Orthop Trauma Surg; 2009 May; 129(5):711-8. PubMed ID: 18427820
[TBL] [Abstract][Full Text] [Related]
18. Dysregulated atrial gene expression of osteoprotegerin/receptor activator of nuclear factor-κB (RANK)/RANK ligand axis in the development and progression of atrial fibrillation.
Cao H; Wang J; Xi L; Røe OD; Chen Y; Wang D
Circ J; 2011; 75(12):2781-8. PubMed ID: 22001292
[TBL] [Abstract][Full Text] [Related]
19. Activation of the receptor activator of the nuclear factor-κB ligand pathway during coronary bypass surgery: comparison between on- and off-pump coronary artery bypass surgery procedures.
Galeone A; Brunetti G; Rotunno C; Oranger A; Colucci S; de Luca Tupputi Schinosa L; Zallone A; Grano M; Paparella D
Eur J Cardiothorac Surg; 2013 Aug; 44(2):e141-7. PubMed ID: 23671202
[TBL] [Abstract][Full Text] [Related]
20. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]